clinical trial · NCT04712643
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche·phase3·active not recruiting·n = 342
Hepatocellular CarcinomaAtezolizumabBecavizumabTransarterial chemoembolization (TACE)
brief summary
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.
started
Mar 12, 2021
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Jan 30, 2026
official title
A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol